Retardation of brain aging by chronic treatment with melatonin

S. C. Bondy, Debomoy Lahiri, V. M. Perreau, K. Z. Sharman, A. Campbell, J. Zhou, E. H. Sharman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Slowing the functional decline in the aging brain is not only relevant to nonpathological senescence but also to a broad range of neurodegenerative diseases. Although disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) are not found in the young adult, they gradually manifest with increasing age. AD, in particular, is an increasing major public health concern as the population ages; therapies that delay disease onset will markedly reduce overall disease prevalence. Aging of the brain has been repeatedly associated with cumulative oxidative damage to macromolecules and to abnormal levels of inflammatory activity. Melatonin has attained increasing prominence as a candidate for ameliorating these changes occurring during senescence. Recent research has focused on supplementation with dietary melatonin designed to elucidate the specific key intracellular targets of age-related inflammatory events, and the optimal means of affording protection of these targets. This report summarizes the progress made in this area.

Original languageEnglish
Pages (from-to)197-215
Number of pages19
JournalAnnals of the New York Academy of Sciences
Volume1035
DOIs
StatePublished - 2004

Fingerprint

Melatonin
Brain
Alzheimer Disease
Aging of materials
Dietary Supplements
Neurodegenerative Diseases
Parkinson Disease
Young Adult
Public Health
Neurodegenerative diseases
Therapeutics
Research
Population
Public health
Macromolecules
Alzheimer's Disease

Keywords

  • Antioxidants
  • Brain aging
  • Inflammation
  • Melatonin
  • Neurodegenerative disease

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bondy, S. C., Lahiri, D., Perreau, V. M., Sharman, K. Z., Campbell, A., Zhou, J., & Sharman, E. H. (2004). Retardation of brain aging by chronic treatment with melatonin. Annals of the New York Academy of Sciences, 1035, 197-215. https://doi.org/10.1196/annals.1332.013

Retardation of brain aging by chronic treatment with melatonin. / Bondy, S. C.; Lahiri, Debomoy; Perreau, V. M.; Sharman, K. Z.; Campbell, A.; Zhou, J.; Sharman, E. H.

In: Annals of the New York Academy of Sciences, Vol. 1035, 2004, p. 197-215.

Research output: Contribution to journalArticle

Bondy, SC, Lahiri, D, Perreau, VM, Sharman, KZ, Campbell, A, Zhou, J & Sharman, EH 2004, 'Retardation of brain aging by chronic treatment with melatonin', Annals of the New York Academy of Sciences, vol. 1035, pp. 197-215. https://doi.org/10.1196/annals.1332.013
Bondy, S. C. ; Lahiri, Debomoy ; Perreau, V. M. ; Sharman, K. Z. ; Campbell, A. ; Zhou, J. ; Sharman, E. H. / Retardation of brain aging by chronic treatment with melatonin. In: Annals of the New York Academy of Sciences. 2004 ; Vol. 1035. pp. 197-215.
@article{54d489a7416a420ba6c8a17dae0f90b0,
title = "Retardation of brain aging by chronic treatment with melatonin",
abstract = "Slowing the functional decline in the aging brain is not only relevant to nonpathological senescence but also to a broad range of neurodegenerative diseases. Although disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) are not found in the young adult, they gradually manifest with increasing age. AD, in particular, is an increasing major public health concern as the population ages; therapies that delay disease onset will markedly reduce overall disease prevalence. Aging of the brain has been repeatedly associated with cumulative oxidative damage to macromolecules and to abnormal levels of inflammatory activity. Melatonin has attained increasing prominence as a candidate for ameliorating these changes occurring during senescence. Recent research has focused on supplementation with dietary melatonin designed to elucidate the specific key intracellular targets of age-related inflammatory events, and the optimal means of affording protection of these targets. This report summarizes the progress made in this area.",
keywords = "Antioxidants, Brain aging, Inflammation, Melatonin, Neurodegenerative disease",
author = "Bondy, {S. C.} and Debomoy Lahiri and Perreau, {V. M.} and Sharman, {K. Z.} and A. Campbell and J. Zhou and Sharman, {E. H.}",
year = "2004",
doi = "10.1196/annals.1332.013",
language = "English",
volume = "1035",
pages = "197--215",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Retardation of brain aging by chronic treatment with melatonin

AU - Bondy, S. C.

AU - Lahiri, Debomoy

AU - Perreau, V. M.

AU - Sharman, K. Z.

AU - Campbell, A.

AU - Zhou, J.

AU - Sharman, E. H.

PY - 2004

Y1 - 2004

N2 - Slowing the functional decline in the aging brain is not only relevant to nonpathological senescence but also to a broad range of neurodegenerative diseases. Although disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) are not found in the young adult, they gradually manifest with increasing age. AD, in particular, is an increasing major public health concern as the population ages; therapies that delay disease onset will markedly reduce overall disease prevalence. Aging of the brain has been repeatedly associated with cumulative oxidative damage to macromolecules and to abnormal levels of inflammatory activity. Melatonin has attained increasing prominence as a candidate for ameliorating these changes occurring during senescence. Recent research has focused on supplementation with dietary melatonin designed to elucidate the specific key intracellular targets of age-related inflammatory events, and the optimal means of affording protection of these targets. This report summarizes the progress made in this area.

AB - Slowing the functional decline in the aging brain is not only relevant to nonpathological senescence but also to a broad range of neurodegenerative diseases. Although disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) are not found in the young adult, they gradually manifest with increasing age. AD, in particular, is an increasing major public health concern as the population ages; therapies that delay disease onset will markedly reduce overall disease prevalence. Aging of the brain has been repeatedly associated with cumulative oxidative damage to macromolecules and to abnormal levels of inflammatory activity. Melatonin has attained increasing prominence as a candidate for ameliorating these changes occurring during senescence. Recent research has focused on supplementation with dietary melatonin designed to elucidate the specific key intracellular targets of age-related inflammatory events, and the optimal means of affording protection of these targets. This report summarizes the progress made in this area.

KW - Antioxidants

KW - Brain aging

KW - Inflammation

KW - Melatonin

KW - Neurodegenerative disease

UR - http://www.scopus.com/inward/record.url?scp=14944370553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14944370553&partnerID=8YFLogxK

U2 - 10.1196/annals.1332.013

DO - 10.1196/annals.1332.013

M3 - Article

VL - 1035

SP - 197

EP - 215

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -